Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
Biocartis submits 510(k) to FDA, expands European hospitals deal with Amgen
December 22, 2016 Off

Biocartis submits 510(k) to FDA, expands European hospitals deal with Amgen

By Dino Mustafić

Biocartis has today strenghten its collaboration with two companies;  J&J’s Jansen and Amgen, as it has submitted 510(k) its diagnostics…

Abzena in licence agreement with USA-based Trieza
December 22, 2016 Off

Abzena in licence agreement with USA-based Trieza

By Dino Mustafić

Abzena has granted USA-based Trieza an exclusive worldwide, royalty bearing, sub-licensable licence to an undisclosed antibody sequence, for exploitation in…

Advanced Oncotherapy happy with technical development of the LIGHT system
December 22, 2016 Off

Advanced Oncotherapy happy with technical development of the LIGHT system

By Dino Mustafić

Advanced Oncotherapy has successfully tested and calibrated programme at ADAM in Geneva, and that made it possible to integrate the…

Horizon’s lung infections antibiotic Quinsair available in Canada for adults with Cystic Fibrosis
December 22, 2016 Off

Horizon’s lung infections antibiotic Quinsair available in Canada for adults with Cystic Fibrosis

By Dino Mustafić

Horizon Pharma and its Canadian affiliate Horizon Therapeutics Canada Limited have brought its inhalation solution for chrnic lung infection Quinsair to Canada.

Quinsair is used for chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF).

Allergan/Ironwood’s enhanced linaclotide CR1 could double Linzess franchise from $1B in U.S. net sales by 2020
December 22, 2016 Off

Allergan/Ironwood’s enhanced linaclotide CR1 could double Linzess franchise from $1B in U.S. net sales by 2020

By Dino Mustafić

Ironwood Pharmaceuticals and Allergan have been testing an irritable bowel syndrome with constipation (IBS-C) drug, a formulation of linaclotide colonic…

FDA accepts Pfizers breast cancer drug supplemental New Drug Application
December 22, 2016 Off

FDA accepts Pfizers breast cancer drug supplemental New Drug Application

By Dino Mustafić

Pfizer is moving forward with Ibrance breast cancer drug as the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA).

Janssen asks FDA approval for psoriatic arthritis drug
December 21, 2016 Off

Janssen asks FDA approval for psoriatic arthritis drug

By Dino Mustafić

Janssen Biotech has  submitted two Supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) seeking approval…

BMS and Calithera Biosciences team up against cancer
December 21, 2016 Off

BMS and Calithera Biosciences team up against cancer

By Dino Mustafić

Bristol-Myers Squibb Company and Calithera Biosciences, Inc., a clinical stage biotechnology company focused on discovering and developing novel small molecule…

Hansa Medical successfully completes Phase II IdeS study; QUITS IdeS study in acquired TTP
December 21, 2016 Off

Hansa Medical successfully completes Phase II IdeS study; QUITS IdeS study in acquired TTP

By Dino Mustafić

Hansa Medical AB has announced completion of a Phase II study entitled “A Phase II Study to Evaluate the Safety,…

Oasmia Pharmaceutical reports positive results from breast cancer drug study
December 21, 2016 Off

Oasmia Pharmaceutical reports positive results from breast cancer drug study

By Dino Mustafić

Oasmia Pharmaceutical, a developer of a new generation of drugs within human and veterinary oncology, today presented positive results from…

Posts pagination

Previous 1 … 3,536 3,537 3,538 … 3,605 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine